<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2A2B9F6E-3217-4B06-9043-58D3BD980395"><gtr:id>2A2B9F6E-3217-4B06-9043-58D3BD980395</gtr:id><gtr:firstName>Una-Marie</gtr:firstName><gtr:surname>Sheerin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100479"><gtr:id>8138A179-50EB-4A10-B778-A77EBD616D83</gtr:id><gtr:title>Whole-Exome Sequencing in Autosomal Recessive Parkinson's Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1100479</gtr:grantReference><gtr:abstractText>Parkinson?s disease (PD) is a common, disabling, incurable neurodegenerative condition. In the last decade it is clear that there is a substantial genetic component to this disorder. Current treatment is palliative and based upon dopamine augmentation. 

I plan to use a technology, called exome sequencing which has recently been developed and becoming increasingly affordable to try and establish the gene responsible for Parkinson?s disease in a group of families. Study of these families is likely to reveal new genes responsible for PD, since we know that these families do not map to any of the known genes for PD.

Finding new genes for Parkinson?s disease, even if they occur only rarely in the general population is of importance, as these genes help us understand the biological pathways, and through this will help identify new drug targets for treatment of this disorder.</gtr:abstractText><gtr:technicalSummary>It is now clear that there is substantial evidence for a genetic component to Parkinson?s disease. Research to date suggests that rare variants account for a significant fraction of unexplained heritability. 

Through the neurogenetics clinic I have identified 30 individuals whose pedigrees suggest an autosomal recessive form of Parkinson?s disease. Previous gene mapping techniques are not suitable for these families. These individuals are either from consanguineous parentages, and have such large areas of homozygosity that autozygosity mapping with positional cloning strategies are not feasible, or they are non-consanguineous and are too small to use linkage based strategies. 

I propose to carry out whole-exome sequencing (the selective resequencing of all exons in a genome) on an affected individual from each family. As exome sequencing will identify potential causal variants, it can be applied in families that are too small to provide meaningful information using linkage, allowing families and even single probands to be analysed jointly, irrespective of allelic heterogeneity. 

The literature suggests that we will identify 400-700 coding non-synonymous variants per exome, which are absent from currently available databases. However, exome data generated at UCL suggests that we will identify approximately 2500 coding novel non-synonymous variants per exome. I will identify genes with both alleles bearing a predicted non-synonymous variant (within homozygous areas for consanguineous individuals), I will further then reduce the pool of candidate variants/genes by filtering variants using functional, expression, and evolutionary data, also incorporating the possibility of genetic heterogeneity. 

A full resolution of the genetic underpinning of PD has yet to be achieved. Rare monogenic variants of common disease contribute eminently to our understanding of complex disorders by helping define and understand pathways that lead to neuronal dysfunction and cdeath.</gtr:technicalSummary><gtr:fund><gtr:end>2014-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>129110</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FA1610E1-AA03-4371-8D07-06DFB0D0BDA6</gtr:id><gtr:title>Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb76623ba9100a6a132a4d8578ef49e"><gtr:id>8bb76623ba9100a6a132a4d8578ef49e</gtr:id><gtr:otherNames>Sheerin UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>pm_15059_29_23180180</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9BAFD2A-0FC3-43A7-9BA6-DBA54465051F</gtr:id><gtr:title>A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>pm_15059_29_23588557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A90A2619-DE33-44F0-BC3A-9F8F7ACE8348</gtr:id><gtr:title>Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/349c44726fe224ca60f332ec47e17fba"><gtr:id>349c44726fe224ca60f332ec47e17fba</gtr:id><gtr:otherNames>Sadnicka A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>pm_15059_29_22523156</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B04D6A4-D94C-4089-ACBB-43440B988B2A</gtr:id><gtr:title>Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2d0f395414b93ca8e16b698d9d8d12"><gtr:id>1e2d0f395414b93ca8e16b698d9d8d12</gtr:id><gtr:otherNames>International Parkinson Disease Genomics Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_15059_29_21292315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD95F986-8880-46F2-A9FD-18B6D8037E41</gtr:id><gtr:title>Study of the genetic variability in a Parkinson's Disease gene: EIF4G1.</gtr:title><gtr:parentPublicationTitle>Neuroscience letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e8088f2d6e90105cd78b127c6516c9f"><gtr:id>2e8088f2d6e90105cd78b127c6516c9f</gtr:id><gtr:otherNames>Tucci A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0304-3940</gtr:issn><gtr:outcomeId>pm_15059_29_22561553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5F7DCDC-3F4B-4831-A772-87D2C952D248</gtr:id><gtr:title>Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d14c3a9646f0da9792d2b4276c13d04a"><gtr:id>d14c3a9646f0da9792d2b4276c13d04a</gtr:id><gtr:otherNames>Moskvina V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>546a76185a7411.61365900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D93D4BCD-3F2F-49CA-BE19-279E5172B53C</gtr:id><gtr:title>The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b45f75b0c7637f862f1b025d4b726505"><gtr:id>b45f75b0c7637f862f1b025d4b726505</gtr:id><gtr:otherNames>Klebe S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_15059_29_23408064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5113FA52-A057-4AB4-8503-B90158F55EF7</gtr:id><gtr:title>A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11291e7208395859a2f8dbcb14e782d8"><gtr:id>11291e7208395859a2f8dbcb14e782d8</gtr:id><gtr:otherNames>Holmans P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_15059_29_23223016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>878C7C77-0E45-4B68-9AAC-AE6FB64FE93B</gtr:id><gtr:title>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>546a761a1eb1c2.88367282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1E8F6AD-8475-495A-AC85-1646D17B1756</gtr:id><gtr:title>Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ca09ebb1473b9780612d7b5d9dafef"><gtr:id>68ca09ebb1473b9780612d7b5d9dafef</gtr:id><gtr:otherNames>Wray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15059_29_22952635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E3C434B-12C0-40F1-9322-8CC4D64C4F22</gtr:id><gtr:title>A two-stage meta-analysis identifies several new loci for Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21954146dfa6bdef021f2fa27d03fd93"><gtr:id>21954146dfa6bdef021f2fa27d03fd93</gtr:id><gtr:otherNames>International Parkinson's Disease Genomics Consortium (IPDGC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>pm_15059_29_21738488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09757D8A-D61E-4897-AD07-D5F9C8CD55F8</gtr:id><gtr:title>Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aeab5dcf8187a67e2a1d2237a3100588"><gtr:id>aeab5dcf8187a67e2a1d2237a3100588</gtr:id><gtr:otherNames>Tsika E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>546a761970d810.74984027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82FC6F54-AE2E-4A72-B518-2AB6911DB4CA</gtr:id><gtr:title>The phenotypic spectrum of DYT24 due to ANO3 mutations.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>546a7618ebd607.45632128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6701B3B8-893E-4841-8FE1-31E1ECD3295B</gtr:id><gtr:title>Paroxysmal dyskinesias revisited: a review of 500 genetically proven cases and a new classification.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc98b863ea1e6ac2e57978c77cd38ad6"><gtr:id>fc98b863ea1e6ac2e57978c77cd38ad6</gtr:id><gtr:otherNames>Erro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>546a7619eb2c46.26740003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB696F2F-DC6E-4C94-B2DA-09837A1B9365</gtr:id><gtr:title>Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d633de923aea18df03c8589daadc941"><gtr:id>6d633de923aea18df03c8589daadc941</gtr:id><gtr:otherNames>Pichler I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_15059_29_23750121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E3C9746-DADB-48C9-A129-A83BD2698297</gtr:id><gtr:title>Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_15059_29_23200863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6BEE08A-2F43-4754-A231-CB3AFE4945C8</gtr:id><gtr:title>ALS2 mutations: juvenile amyotrophic lateral sclerosis and generalized dystonia.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb76623ba9100a6a132a4d8578ef49e"><gtr:id>8bb76623ba9100a6a132a4d8578ef49e</gtr:id><gtr:otherNames>Sheerin UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>546a76194697a2.75912585</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6F7E746-C0F7-4DA5-888E-C223DC4C54E0</gtr:id><gtr:title>Screening for VPS35 mutations in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bb76623ba9100a6a132a4d8578ef49e"><gtr:id>8bb76623ba9100a6a132a4d8578ef49e</gtr:id><gtr:otherNames>Sheerin UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_15059_29_22154191</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BA3BCCF-D686-4B24-A3CB-9C1E91816AB3</gtr:id><gtr:title>Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65e7392b7dab0adf61a43ce690e8d2b3"><gtr:id>65e7392b7dab0adf61a43ce690e8d2b3</gtr:id><gtr:otherNames>Rubio-Agusti I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn><gtr:outcomeId>pm_15059_29_23523105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC800AD2-FBA7-4CAA-95E8-179A2C25C47D</gtr:id><gtr:title>Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ed587de899b30ad5f3dce3fc99e9d0a"><gtr:id>5ed587de899b30ad5f3dce3fc99e9d0a</gtr:id><gtr:otherNames>Keller MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_15059_29_22892372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24BEB48A-1353-4BF1-A22B-732CA1C8378A</gtr:id><gtr:title>The entity of parkinsonism and associated lipomatosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3b37a1ea4c6bb2dd69d484101a8d28c"><gtr:id>d3b37a1ea4c6bb2dd69d484101a8d28c</gtr:id><gtr:otherNames>Stamelou M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>546a761a463879.49364648</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DB8AECA-3C7B-4193-8462-ECE2D29058FE</gtr:id><gtr:title>Tau acts as an independent genetic risk factor in pathologically proven PD.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80bdbfdd0b1d93ff7f53295d25d425e7"><gtr:id>80bdbfdd0b1d93ff7f53295d25d425e7</gtr:id><gtr:otherNames>Charlesworth G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_15059_29_22221882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5E057D3-6C86-4637-9AB1-66B8D47A020F</gtr:id><gtr:title>Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eacf2f251ce8f5b9824dfa60f488e0b0"><gtr:id>eacf2f251ce8f5b9824dfa60f488e0b0</gtr:id><gtr:otherNames>Mittag F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_15059_29_22777693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>942BAE7C-F361-46B0-95EB-88406990F7CB</gtr:id><gtr:title>Young-onset parkinsonism due to homozygous duplication of a-synuclein in a consanguineous family.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a710ca1824f44073ef7bb8d23ab87321"><gtr:id>a710ca1824f44073ef7bb8d23ab87321</gtr:id><gtr:otherNames>Kojovic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>pm_15059_29_23283657</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E68A67E-1814-4D23-B6DA-B89F260621DC</gtr:id><gtr:title>Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95c25a60693a992681a42b54c91bff9e"><gtr:id>95c25a60693a992681a42b54c91bff9e</gtr:id><gtr:otherNames>Dong J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>546a7618c18779.38310632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73D04861-0F1D-4001-80DB-F643D1590B4F</gtr:id><gtr:title>Analysis of Parkinson's disease brain-derived DNA for alpha-synuclein coding somatic mutations.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad6d814d95a541c7e3a165cbafd92058"><gtr:id>ad6d814d95a541c7e3a165cbafd92058</gtr:id><gtr:otherNames>Proukakis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>546a7619989060.86725653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D978F08E-63F0-41A0-BAF2-9AD6A5139602</gtr:id><gtr:title>Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d9b30d099d6baedd937038ef4d2f899"><gtr:id>9d9b30d099d6baedd937038ef4d2f899</gtr:id><gtr:otherNames>Beilina A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>546a76191ebcb7.55886971</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E708178-652B-431C-A947-B762EFB3B1B7</gtr:id><gtr:title>Genetic comorbidities in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf8b293c57e2abbe75629b0924e21ef0"><gtr:id>cf8b293c57e2abbe75629b0924e21ef0</gtr:id><gtr:otherNames>Nalls MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>546a7618885c41.47068614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA20F61B-1D33-4D4E-81AA-5D1EBA4717A1</gtr:id><gtr:title>Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/553f7ec4568e90f2c7e4cc3fc62a1bd1"><gtr:id>553f7ec4568e90f2c7e4cc3fc62a1bd1</gtr:id><gtr:otherNames>Carvajal-Gonz?lez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>546a7619c0e417.19804569</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100479</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>